Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer

References

• Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059–67.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 2011;376:1989–99.
   Web of Science ®Google Scholar
• Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur J Cancer 2012;48:187–95.
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008;19:420–32.
   PubMed Web of Science ®Google Scholar
• Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 2010;26(Suppl 3):3–20.
   PubMedGoogle Scholar
• Lund T, Abildgaard N, Delaisse JM, Plesner T. Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol 2010; 151:92–3.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, et al. The Medical Research Council Myeloma IX trial: The impact on treatment paradigms. Eur J Haematol 2012;88:1–7.
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303–17.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516–20.
   PubMed Web of Science ®Google Scholar
• Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973–9.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 2004;100:44–52.
   PubMed Web of Science ®Google Scholar
• Abrahamsen B. Bone freezing and bisphosphonates. Maturitas 2011;69:1–2.
   PubMed Web of Science ®Google Scholar
• Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: A potential complication of Alendronate Therapy. J Clin Endocrinol Metab 2005;90:1294–301.
   PubMed Web of Science ®Google Scholar
• Soe K, Plesner T, Jakobsen EH, Hansen CT, Jorgensen HB, Delaisse JM. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?. J Bone Miner Res 2013;28:1738–50.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691–5.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Hadji P. Managing bone health with zoledronic acid: A review of randomized clinical study results. Climacteric 2011;14:321–32.
   PubMed Web of Science ®Google Scholar
• Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 2011;79:175–88.
   PubMed Web of Science ®Google Scholar
• Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T. Multiple myeloma: Changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol 2010;84:412–20.
   PubMed Web of Science ®Google Scholar
• Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001;16:1575–82.
   PubMed Web of Science ®Google Scholar
• Andersen TL, Sondergaard TE, Skorzynska KE, gnaes-Hansen F, Plesner TL, Hauge EM, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009;174:239–47.
   PubMed Web of Science ®Google Scholar
• Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 2010; 148:551–61.
   PubMed Web of Science ®Google Scholar
• Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;109:1090–6.
   PubMed Web of Science ®Google Scholar
• Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review. J Cancer Res Ther 2010;6:31–5.
   PubMed Web of Science ®Google Scholar